. 2014 Oct 21;20(39):14255–14262. doi: 10.3748/wjg.v20.i39.14255

Table 3.

Published series on laparoscopic and robotic pancreaticoduodenectomy with at least five cases of adenocarcinoma (variables reported for entire series, not just malignant cases)

Study	Cases	Malignant pathology	Mean node harvest (range)	R0 margin	Mean blood loss (mL)	Mean length of stay (d)	Pancreatic fistula rate	Mortality	Overall morbidity	Mean operative time (min)
²Bao et al[77]	28	4 AC	15 (8-32)¹	63%	100¹	7 ¹	21%	7%	NR	431¹
²Bao et al[77]	28	10 PDAC	15 (8-32)¹	63%	100¹	7 ¹	21%	7%	NR	431¹
Kim et al[78]	100	4 AMP	13 (7-34)	100%	NR	14	6%	1%	25%	487
Kim et al[78]	100	7 PDAC	13 (7-34)	100%	NR	14	6%	1%	25%	487
Asbun et al[76]	53	8 AMP	23 (SD 10)	95%	195	8	17%	6%	22%	608
Asbun et al[76]	53	22 PDAC	23 (SD 10)	95%	195	8	17%	6%	22%	608
²Chalikonda et al[79]	30	14 adeno-carcinoma	13 (1-37)	100%	486	10	7%	3%	30%	476
²Lai et al[80]	20	5 AC	10 (SD 60)	73%	247	14	35%	0%	50%	492
²Lai et al[80]	20	7 PC	10 (SD 60)	73%	247	14	35%	0%	50%	492
²Zeh et al[81]	50	9 AMP	17 (5-37)	89%	350¹	10	20%	2%	30%³	568¹
²Zeh et al[81]	50	14 PDAC	17 (5-37)	89%	350¹	10	20%	2%	30%³	568¹
Suzuki et al[72]	6	4 AMP	18 (16-27)	100%	471¹	23¹	33%	0%	33%	581¹
Suzuki et al[72]	6	1 PDAC	18 (16-27)	100%	471¹	23¹	33%	0%	33%	581¹
Ammori et al[15]	7	2 AMP	20.8 (11-32)	NR	350	11	14%	0%	29%	628
Ammori et al[15]	7	5 PDAC	20.8 (11-32)	NR	350	11	14%	0%	29%	628
²Giulianotti et al[82]	60	15 AMP	18 (5-45)	92%	394	22	31%	14%	31%	421
²Giulianotti et al[82]	60	27 PDAC	18 (5-45)	92%	394	22	31%	14%	31%	421
Kendrick et al[83]	62	8 AMP	15 (6-31)	89%	240	7	18%	2%	42%	368¹
Kendrick et al[83]	62	31 PDAC	15 (6-31)	89%	240	7	18%	2%	42%	368¹
Cho et al[66]	15	1 AMP	19 (NR)	100%	445	16	13%	0%	27%	338
Cho et al[66]	15	4 PDAC	19 (NR)	100%	445	16	13%	0%	27%	338
Palanivelu et al[84]	75	29 AMP	14 (8-22)	97%	74	8	7%	1%	27%	357
Palanivelu et al[84]	75	33 PDAC	14 (8-22)	97%	74	8	7%	1%	27%	357
Pugliese et al[67]	19	4 AMP	12 (4-22)	100%	180	18	23%	0%	37%	461
Pugliese et al[67]	19	6 PDAC	12 (4-22)	100%	180	18	23%	0%	37%	461
Dulucq et al[75]	25	4 AMP	18 (NR)	100%	107	16	5%	5%	32%	287
Dulucq et al[75]	25	11 PDAC	18 (NR)	100%	107	16	5%	5%	32%	287
Staudacher et al[69]	7	1 PDAC	26 (16-47)	100%	325	12	0%	0%	0%	416
Gagner et al[85]	10	3 AMP	7 (3-14)	100%	NR	22	17%	0%	50%	510
Gagner et al[85]	10	4 PDAC	7 (3-14)	100%	NR	22	17%	0%	50%	510

Median;

Robotic hybrid;

Clavien III/IV. AC: Ampullary cancer; PDAC: Pancreatic ductal adenocarcinoma; AMP: Ampullary adenocarcinoma/ampullary dysplastic adenoma; NR: Not reported; PC: Pancreatic cancer.